Skip to main content

Table 1 Summary of the history of clinical manifestation of the SLE patients in cohort 3

From: The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus

Phenotype

EUR

Non-EUR

N

Affected patients, n (%)

N

Affected patients, n (%)

ORa (95% CI)

P valueb

Renal

320

75 (24.4%)

243

81 (33.3%)

1.60 (1.11–2.32)

0.01

Neurological

330

36 (10.9%)

244

42 (17.2%)

1.67 (1.05–2.74)

0.03

Haematological

366

185 (50.5%)

268

106 (39.6%)

0.65 (0.47–0.89)

0.007

dsDNA positivity

370

143 (38.6%)

270

83 (30.7%)

0.70 (0.51–0.98)

0.04

Admission ratec

351

140 (39.9%)

196

86 (43.9)

1.20 (0.84–1.71)

0.31

Biologics ever neededd

332

23 (6.9%)

239

12 (5.0%)

0.70 (0.34–1.43)

0.33

  1. Summary of available clinical history for the 656 study participants from cohort 3 since their disease diagnosis and up to the time of their visit. Data were stratified by study cohort
  2. CI confidence interval, EUR patients of European ancestry, non-EUR patients of non-European ancestry, SLE systemic lupus erythematosus
  3. aOdds ratio (OR) in non-European patients
  4. bP values calculated using Pearson’s chi-squared test
  5. cAdmission defined as any patient requiring hospital admission specifically for SLE in the 5 years prior to and including the date of their clinic visit at which the blood sample was taken
  6. dPatients treated with biologic drugs at any time since their disease diagnosis